

ANTIRETROVIRAL PRESCRIPTION PROFILE AND ADHERENCE TO GUIDELINES

Hernández-Sánchez A, Arteta-Jiménez M, Molina-García T.
Pharmacy department. Getafe University Hospital. Madrid. Spain.

OBJECTIVES

- To **DESCRIBE THE DIFFERENCES BETWEEN THE YEARLY ANTIRETROVIRAL THERAPY (ART) RECOMMENDATIONS** from a Spanish HIV study group (GESIDA) from 2010 to 2012.
- To **ANALYSE THE ART PRESCRIPTION PROFILE (PP)** in naïve patients for 2010 and 2011 (PP-2010; PP-2011) and **EVALUATE THE ADHERENCE** to GESIDA recommendations.

STUDY DESIGN

- ↳ Seventy naïve patients (36 in 2010; 34 in 2011) were included in a retrospective observational study of ART and laboratory/microbiology parameters between 2010 and 2011, in a 450-bed tertiary hospital.
- ↳ The latest GESIDA recommendations (January 2010, 2011 and 2012) were reviewed.
- ↳ Microsoft Excel 2007 and SPSS Statistics 19.0 were used for statistical analysis.

RESULTS

RECOMMENDED PREFERRED THERAPIES AVAILABILITY		
GESIDA-2010	GESIDA-2011	GESIDA-2012
16	9	9

- While GESIDA-2010 has a freer combinatory process between antiretroviral drugs, GESIDA-2011 and GESIDA-2012 narrow it to only certain combinations.

TREATMENT RECOMMENDATIONS ACCORDING TO CD4 COUNT		
CD4 COUNT / GESIDA	2010	2011-2012
< 350 cells/ μ l	Recommend	Recommend
350-500 cells/ μ l	Do not recommend*	Reccomend*
> 500 cells/ μ l	Defer	Do not recommend*

* Except certain circumstances.

Therapies	PRESCRIPTION PROFILE ADHERENCE TO GUIDELINES							
	PP-2010				PP-2011			
	GESIDA 2010		GESIDA-2011		GESIDA-2011		GESIDA-2012	
Preferred	34		32		27		28	
	100%		92%		79%		82%	
Alternative	2		1		0		0	
Out guidelines	0	0%	3	8%	7	21%	6	18%

- PP-2010 adhered to GESIDA-2010 in a 100%, however PP-2011 adherence to GESIDA-2011 fell to 79% ($\alpha=0,004$).
- PP-2011 has a better compliance to GESIDA-2012 preferred therapies rather than to GESIDA -2011 (82% vs 79%) ($\alpha=0,1$).

CONCLUSIONS

- The last three years GESIDA guidelines have tended to reduce the number of recommended therapies available for treatment and encourage to treat patients with higher CD4 count.
- According to our results, PP-2011 tended to adhere more to the following year GESIDA recommendations (not significant). The high percentage of adherence of PP-2010 to the same year guidelines (100%) might be partly explained because the combinations available were nearly twice as many as next year recommendations.
- GESIDA is a reference for ART, but given its once-a-year publication, continuous updated information from current investigations becomes necessary for prescribing.